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AKR1C3 inhibition by curcumin, 





Background: Aldo-keto reductase 1C3 (AKR1C3) has been shown to be overexpressed in 
cancers due to its regulatory roles in cell proliferation and differentiation.  Curcumin, known to 
have anti-tumour properties, and its analogues demethoxycurcumin (DMC) and 
bisdemethoxycurcumin (BDMC) were studied to determine their inhibitory effects on the 
AKR1C3 enzyme. 
Methods: AKR1C3 was purified and analysed to determine its protein concentration in 
transformed Escherichia coli (E. coli) cells.  Enzyme assays equaling 1 mL contained 2.82 mg/mL 
AKR1C3, 50 μM of 3 mM NADPH, and varying volumes of potassium phosphate (50 mM, pH 
6.5), 9,10-phenanthrenequinone (PQ), and inhibitors were measured at 340 nm.  The Vmax, Km, 
KI, and 2 of AKR1C3 in the presence and absence of inhibitors were determined using a non-
linear regression analysis on Fig.P Software. 
Results:  PQ alone found Vmax = 0.47 IU/mg, Km = .435 μM, Ki = 6.29 μM, and 2 = 0.946.  Inhibitor 
potency was BDMC > DMC > curcumin in the presence of 1 μM PQ.  Further analysis of BDMC 
indicated mixed inhibition (Vmax = 0.46 IU/mg, Km = .406 μM, Ki = 1.59 μM, and 2 = 0.970).  Further 
analysis of PQ at higher concentrations found a divergence from Michaelis-Menten kinetics, 
with a decrease in AKR1C3 activity after Vmax was reached. 
Conclusions:  BDMC was the more potent inhibitor of AKR1C3 in transformed E. coli compared 
to DMC and curcumin.  The results suggest mixed inhibition of AKR1C3 in the presence of 
BDMC.  Additional analysis of PQ at higher concentrations saw a loss of Michaelis-Menten 
kinetics as the activity of AKR1C3 decreased after reaching Vmax.  This requires further 
examination.   




Aldo-keto reductase 1C3 (AKR1C3) is a 36.8 
kD member of the aldo/keto reductase 
superfamily AKR1C that catalyses alcohols 
from aldehydes and ketones in the 
presence of NAD(P)H [1].  AKR1C3 has an 
influential role in several cell signalling 
pathways that can influence cell 
proliferation and differentiation.  
Prostaglandins (PG) PGH2 and PGD2 are 
converted to PGF2α and 9α,11β-PGF2α, 
respectively, in the presence of AKR1C3 
(Fig. 1a) [2, 3], while weak androgens and 
oestrogens (4-androstone-3,17-dione and 
oestrone) are converted into potent ones 
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(testosterone and 17β-oestradiol) due to 
the co-activation of the androgen 
receptor (AR) and oestrogen receptor (ER) 
(Fig. 1b) [4, 5].   
These conversions can be problematic in 
tumorous cells, as the resulting products 
can influence the rate of gene transcription 
[6].  Overactivation of gene transcription 
due to AKR1C3 overexpression has been 
found in a myriad of cancers including 
breast, colon, colorectal, endometrial, 
prostate, and acute myeloid luekeaima [7, 
8].  In the absence of AKR1C3 PGD2 can be 
converted to 15-deoxy-Δ12,14-PGJ2 (PGJ2), 
which can bind to the peroxisome 
proliferator-activated receptor (PPAR) γ [9, 
10].  PPARγ is then able to promote cellular 
differentiation and apoptosis [9].  This 
relationship between AKR1C3 and cell 
signalling pathways suggests 
overexpression of tumorous cells could be 
impeded with the inhibition of AKR1C3.          
Curcumin(Fig. 2a), a polyphenol from the 
rhizome of the turmeric plant, has been 
shown to contain anti-inflammatory, 
antioxidant, and anti-tumorous activities 
[11].  Several in vitro and in vivo studies 
have been performed to determine 
curcumin’s efficacy as a therapeutic 
option for cancer [12-14].  However, due to 
its poor bioavailability and stability in vivo 
[12, 15-16], it has not seen much success in 
clinical trials.  As such, curcumin analogues 
have been used to greater effect.   
The naturally occurring curcumin 
analogues demethoxycurcumin (DMC) 
(Fig. 2b) and bisdemethoxycurcumin 
(BDMC) (Fig. 2c), have not been examined 
in the AKR1C superfamily, but have tested 
on cancer cells to a positive effect [17].  
BDMC has also shown to be more stable in 
rat livers than curcumin and DMC [15].  This 
suggests BDMC may have a greater 
bioavailability as well.  While curcumin has 
been studied in prostate cells on AKR1C2 
activity [18], neither curcumin, DMC, nor 
BDMC has been utilised to inhibit AKR1C3 
activities, despite AKR1C3 overexpression in 
a variety of cancers.      
This study aimed to examine the inhibitory 
effects of curcumin, DMC, and BDMC on 
AKR1C3 expression in transformed 
Escherichia coli (E. coli) cells and determine 
the type of inhibition that occurred.  Such 
evidence could provide future studies with 
valuable information for the development 
Figure 1.  AKR1C3 influence over cellular pathways.  (a) Prostaglandin synthesis in the presence and absence of AKR1C3.    
(b) Androgen synthesis in the presence of AKR1C3.  Abbreviations: Aldo-keto reductase 1C3 (AKR1C3; Androgen receptor 
(AR); Oestrogen receptor (ER);  Mitogen-activated protein kinase (MAPK); Nuclear factor κB (NF-κB); Peroxisome proliferator-
activated γ receptor (PPARγ). 
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and optimisation of curcumin-based 
therapeutics in cancer patients.   
Methods 
Cell Culture and Purification 
E. coli cells BL21(DE3) (New England Biolabs 
UK) containing the human AKR1C3 enzyme 
(pET21b-AKR1C3) with a His-tag were 
grown overnight in an orbital shaker at 300 
RPM and 37°C and transferred into three 6 
mL bottles of L-broth and ampicillin (Amp)R 
(100 μg/mL).  Cells were shaken and grown 
overnight at 37°C before transferring into 
400 mL L-broth+Amp and centrifuged for 45 
minutes at 4500 RPM.  The resulting pellet 
was stored at -80°C.   
The pellet was resuspended in accordance 
with the manufacturer’s instructions upon 
addition of 8 mL of BugBuster, a protease 
inhibitor cocktail tablet, supplied by Sigma-
Aldrich (Darmstadt, Germany).  Upon 
removal from the room temperature water 
bath, the suspension was extracted and set 
aside as Solubilised Bacteria (SB).  The 
remaining sample was split into two 
eppendorf tubes and spun at 30,000 g for 
25 minutes at 10°C.  The resulting 
supernatant was removed and set aside as 
Supernatant (Sup).  Both the Sup and SB 
were frozen.  The homogenate was further 
purified using a His-select Ni2+ resin column 
(Sigma-Aldrich, Darmstadt, Germany) per 
the manufacturer’s instructions.  The wash 
buffer comprised of 50 mM sodium 
phosphate monobasic monohydrate at 
300 mM NaCl, pH 8.0, while the elution 
buffer additionally contained 100 mM of 
Imidazole, pH 8.0.  Eight elutions of 1 mL 
were collected and analysed for protein 
(P) concentration.   
Protein Estimation 
A standard curve was created using a 
Bradford Assay and bovine serum albumin 
(BSA) from Bio-Rad Laboratories, as seen in 
the supplementary material (Fig. 1).  SB, 
Sup, and P samples were additionally 
analysed (10 μL of sample, 40 μl distilled 
water, and 950 μL of Bradford Reagent).  All 
measurements were taken at 595 nm on a 
Jenway 7200 visible spectrophotometer 
(Stone, Staffordshire, UK) and performed in 
triplicate.  
To determine the protein concentrations of 
AKR1C3 in SB, Sup, and P, each sample was 
diluted to 1 mg/ml with distilled water.  The 
samples were further diluted to 0.5 mg/mL 
[100 μL sample, 100 μL sample buffer 
(Sigma S3401, Sigma-Aldrich, Darmstadt, 
Germany), and 100 μL Laemmli Blue].  They 
were then heated at 90°C for 
approximately 7 minutes and placed on 
ice before electrophoresis was performed.   
Gel Electrophoresis 
The Bio-Rad Laboratories gel 
electrophoresis tank was assembled and 
loaded according to the manufacturer’s 
instructions.  SB, Sup, and P samples were 
loaded at 10 μg per lane.  The gel was run 
at 150 V for 45 minutes before being left 
overnight in 30 mL of EZ blue staining 
reagent (Sigma-Aldrich, Darmstadt, 
Germany). 
Figure 2. Chemical structure of curcumin (a), 




Activity of AKR1C3 
Protein activities of AKR1C3 were 
determined by measuring the oxidation of 
NADPH (ε = 6220 M-1 cm-1) at 340 nm on a 
Jenway 7315 spectrophotometer (Stone, 
Staffordshire, UK) at room temperature.  The 
NADPH solution had been made in distilled 
water from a 1M NADPH stock to achieve a 
final concentration of 3 mM.  The resulting 
solution was made slightly alkaline with the 
addition of NaOH (4 μL) to stabilise said 
solution.  The assay buffer was potassium 
phosphate (50 mM, pH 6.5).  The binding 
substrate was 1 mM stock of 9,10-
phenanthrenequinone (PQ) in dimethyl 
sulfoxide (DMSO).  50 μL of 3 mM NADPH 
was used for every assay, while 20 μL of 2.82 
mg/mL AKR1C3 was also used.  Volumes of 
potassium phosphate, PQ, and inhibitors 
varied to ensure the total volume of the 
enzyme reaction was equal to 1 mL. 
AKR1C3 Inhibitors  
The inhibitors curcumin, DMC, and BDMC 
were added once a Michaelis-Menten 
curve was established for AKR1C3 activity 
with PQ as its substrate.  A 10 mM solution of 
curcumin was made in 5 mL DMSO .  10 mM 
solutions of DMC and BDMC were both 
products of Sigma-Aldrich (Darmstadt, 
Germany). All three inhibitors were kept out 
of the light and stored in 4°C.  The total 
volume of buffers, substrates, AKR1C3, and 
inhibitors always was equal to 1 mL.    
Statistical Analysis and Imaging 
A non-linear regression analysis was 
performed to determine the Vmax, Km, KI, 
and 2 of AKR1C3 activities using Fig.P 
Software (Hamilton, Ontario, Canada).   
These constants were found with PQ 
concentrations up to 25 μM and BDMC up 
to 50 μM.   
Protein purification intensity was analysed 
using Image Processing and Analysis in 
Java (Image J) (National Institute of Health, 
Maryland, USA).  AKR1C3 structure was 
rendered using Visual Mode Dynamics 
Imaging Software (University of Illinois, 
Urbana-Champaign, USA).  The code was 
obtained from the Protein Data Bank, file 
number 1RY0. 
Results 
Protein Purification  
The AKR1C3 enzyme was purified and 
eluted into eight different eppendorf tubes.  
The elution profile (Fig. 2 supplementary 
material) shows the highest protein 
concentration of AKR1C3 was collected 
during the second and third elutions, which 
were pooled together.  The resulting gel 
(Fig. 3) showed the purified AKR1C3 to be 
roughly 35.5 kD, which is near the 
approximate molecular mass of 37 kD for 
AKR1C3, indicating the protein has been 
successfully purified.  The Sup and SB also 
had bands around 35.5 kD, in addition to 
bands with greater and less molecular 
weight. 
Determination of Unknown Samples 
The protein concentrations of SB, Sup, and 
P (Table 1) were calculated based upon 
the BSA standard curve found in Figure 1 of 
the supplementary material.  These 
concentrations were then used to 
calculate the amount of protein per 
volume in the subsequent enzyme assays.    
 
Figure 3.  Electrophoresis of unknown samples.  Thick bands 
around 37 kD indicate the presence of AKR1C3.  
Abbreviations: Molecular Weight (MW), Solubilised Bacteria 




The activity of AKR1C3 was determined by 
measuring the absorbance of the oxidation 
reaction of NADPH at 340 nm.  The mean 
absorbance was used to calculate the 
activity via the equation: 
The rates of activity were then graphed to 
determine the V0, Vmax, Km, and KI from the 
resulting Michaelis-Menten curve and 
Lineweaver-Burk plots.  On the Michaelis-
Menten curve, Vmax is the maximum 
velocity the enzyme reached, while the Km 
is one half of Vmax.  These could then be 
used to determine V0 from the equation: 
 
The type of inhibition was confirmed by 
Lineweaver-Burk plot equation: 
 
 
which was able to show if Vmax or Km was 
altered in reactions performed in the 
presence of an inhibitor.  KI could also be 




whereby [I] was the concentration of the 
inhibitor.  
AKR1C3 with Substrate PQ 
Reactions with AKR1C3, NADPH, and PQ 
were measured using 20 μL of AKR1C3 (2.82 
mg/mL) and PQ concentrations ranging 
from 0.25 μM to 10 μM.  The resulting mean 
activities of AKR1C3 formed a Michaelis-
Menten curve (Fig. 4a), where Km = 1.84 
(μM) and Vmax = 0.561 (IU/mg).  This was 
calculated from the equation 
y = 3.273x + 1.7819 
(R2 = 0.9776) as found from the Lineweaver-
Burk plot (Fig. 4b).  The Lineweaver-Burk plot 
was also established as the baseline activity 
of AKR1C3 with PQ to compare it with 
further reactions involving inhibitors.   
AKR1C3 and Inhibitors  
Using the value of the Michaelis-Menten 
constant, Km, for PQ, the activity of AKR1C3 
was tested in the presence of 1 μM PQ and 
varying concentrations of curcumin, DMC, 
and BDMC ranging from 0.25 μM to 80 μM.  
Raw data can be found in the 
supplementary information.  Figure 5 shows 
the activity percentage of curcumin, DMC, 
and BDMC, as the daily AKRC13 and PQ 
only standard would vary based on the 
room temperature.   
The data suggested BDMC was the most 
effective inhibitor, with almost complete 
inhibition of AKR1C3 activity at 30 μM (Fig. 
5c), followed by DMC with no AKR1C3 
activity at 80 μM (Fig. 5b).  Curcumin is the 
least effective, with some AKR1C3 activity 





DMC also appeared to have a steeper 
gradient, suggesting a higher V0 (Fig. 5d).  
As BDMC was the more potent inhibitor, it 
was used for further experimentation. 
AKR1C3, PQ, and BDMC 
Having established that BDMC was our 
most potent inhibitor, the activities of 
AKR1C3 with a varying substrate 
concentration and constant inhibitor 
concentration were measured.  10 μM of 
BDMC was used, as it was approximately 
halfway between complete and no 
inhibition of AKR1C3.  PQ concentrations 
ranged from 0.5 μM to 5 μM. 
 
 
Interestingly, there was a peak of activity 
around 1 μM PQ, and then decreasing 
rates of activity until it was almost non-
existent (Fig. 6a).  This result, combined with 
a data-point at 10 μM for PQ alone (Fig. 
4a), led us to extend the analysis of PQ 
alone with AKR1C3.   
AKR1C3 and PQ up to 25 μM 
A final measurement of 25 μM PQ with no 
inhibitors found the activity of AKR1C3 had 
decreased, in divergence with Michaelis-
Menten kinetics (Fig. 6b).  Using the 
equation 
Figure 4.  Mean Activity of PQ up to 10µM.  Calculations based upon 20µL of purified AKR1C3 (n = 3 – 5).  Error bars 
indicate standard deviation.  (a) Michaelis-Menten curve where Km = 1.84 μM and Vmax = 0.561 (IU/mg) (b) Lineweaver-







analysis of AKR1C3 and PQ alone found 
Vmax = 0.47 IU/mg, Km = .435 μM, Ki = 6.29 μM, 
V0 = 0.09 IU/mg and 2 = 0.946 (Fig. 7a), 
while  AKR1C3, 1 μM PQ, and up to 50 μM 
BDMC resulted in Vmax = 0.46 IU/mg, Km = 
.406 μM, Ki = 1.59 μM, V0 = 0.33 IU/mg and 2 
= 0.970  (Fig. 7b).  This indicated mixed 
inhibition of AKR1C3 by BDMC. 
Discussion 
The enzyme AKR1C3 has been found to be 
overexpressed in a variety of cancers and 
diseases [7, 8], indicating that it has a 
regulatory role in cell proliferation and 
differentiation.  Theoretically, the ability to 
inhibit AKR1C3 overexpression could 
prevent disease progression and possibly 
result in remission.  Curcumin and its 
analogues have shown anti-tumour and 
anti-inflammation properties [11] but has 
not been specifically studied in the 
inhibition of AKR1C3.  The relationship 
between the inhibitory agents curcumin, 
DMC, and BDMC AKR1C3 was thereby 
explored using PQ as a substrate and 
NADPH as a co-activator.   
We observed inhibitory activity at 
concentrations as low as 10 μM when 
applied in conjunction with 1 μM PQ.  
Inhibitory potency indicated BDMC > DMC 
> curcumin, which has been shown in 
matrix metalloproteinases (MMPs) and 
urokinase plasminogen activator (uPA) [18] 
but is contradictive to potency results 
targeting tumour necrosis factor (TNF)-
induced nuclear factor κB (NF-κB) [13].  This 
suggests the structure of the target 
molecule for curcumin, DMC, and BDMC is 
significant in determining the potency of 
the three curcuminoids.  
(c)                     (d)   
Figure 5.  Activity (IU/mg) percentages of (a) Curcumin (R2 = 0.9346), (b) Bisdemethoxycurcumin (R2 = 0.9768), (c) Demethoxycurcumin (R2 = 
0.8964) and (d) Combined when administered in conjunction with 1µM PQ.  Activity of AKR1C3 decreases with increasing concentrations of the 
inhibitors (n = 2 – 5).  Error bars indicate the coefficient of variation. 
+ 
+ 
(a)                   (b) 
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Three amino acid loops near the active site 
of AKR1C3 allow for a flexibility in binding 
ligands, as does the existence of three sub-
pockets within the active site (Fig. 8) [19, 
20].  These subpockets vary in size and 
amino acid residues which provides 
multiple binding sites for ligands of different 
structures [20].  As curcumin, DMC, and 
BDMC only differ in the electron donating 
methoxy groups – curcumin has two in the 
ortho position, DMC has one, and BDMC 
contains none [13] – it  would be expected 
that these methoxy groups affect the 
binding capabilities and potencies when 
applied to AKR1C3.  The lack of one 
methoxy group in DMC and two in BDMC 
may increase the bioavailability, as seen in 
rat livers [15], due to the stability of the aryl 
rings on either side of the β-diketone 
moiety. 
Historically, curcumin has been shown to 
display competitive and non-competitive 
inhibition within cells depending upon the 
target [21, 22].  Meanwhile, Lovering et al. 
Figure 6.  PQ Activity (IU/mg) with and without BDMC. (a) Activity of PQ + 10 µM Bisdemethoxycurcumin.  PQ 
concentrations ranging from 0.5 µM to 5 µM.  Error bars indicate standard deviation (n = 3 – 5) (b)  PQ activity (IU/mg) 
up to 25 μM.  Calculations based upon 20µL of purified AKR1C3.  The decrease in activity suggests self-inhibition at 





[19] has found mixed inhibition of the 
AKR1C3 enzyme using non-steroidal anti-
inflammatory drugs (NSAIDs), which was 
suggestive of a second inhibitor-binding 
site on AKR1C3.  These varying results imply 
AKR1C3 could be inhibited by curcumin in 
any manner.  The current results indicated 
a type of mixed inhibition.  Competitive 
inhibition was observed for the 
curcuminoids regarding AKR1C3, as there 
was essentially no change in the Vmax for 
AKR1C3 in the presence of the inhibitor 
compared to without the inhibitor (Vmax = 
0.46 IU/mg and 0.47 IU/mg, respectively) 
while uncompetitive inhibition was 
observed in the decreased Km value for the 
reaction with curcuminoids (Km = .406 μM 
and .435 μM).  Mixed inhibition of the 
curcuminoids when applied to AKR1C3 
may be possible due to its elastic structure.       
This flexibility may also account for the 
unexpected activity we observed upon 
increasing the concentration of PQ and 
BDMC. 
Results obtained when the concentration 
of BDMC remained constant at 10 μM and 
PQ concentrations ranged from 0.5 μM to 5 
μM were surprising, as we predicted the 
activity of AKR1C3 to increase as we 
increased the concentration of PQ.  
However, our results showed peak activity 
of AKR1C3 occurred at 1 μM PQ, before a 
decrease in activity was observed at 
increasing concentrations, with almost no 
activity observed starting at 3 μM PQ.  
Subsequently, we increased the 
concentration of PQ in the absence of any 
inhibitor to observe the activity of AKR1C3 
in the presence of higher substrate 
concentrations.  This led to a discovery that 
our AKR1C3 enzyme did not follow 
Michaelis-Menten kinetics and began to 
decrease in activity upon reaching Vmax.   
This decrease in activity suggests AKR1C3 
may be self-inhibiting once it has reached 
substrate saturation.  This could be possible 
be due to a second inhibitor-binding site, as 
suggested by Lovering [19], which may be 
hidden until substrate saturation is 
achieved.  Upon saturation, the malleable 
loops may reveal a self-inhibiting binding 
site that prevents AKR1C3 from 
overexpressing.  This could also explain why 
there is AKR1C3 overexpression in some 
diseases and not others.  Those with 
disease-causing AKR1C3 overexpression 
could have an inactive or inhibited 
potential concealed binding site that 
allows for self-inhibition of AKR1C3.  Further 
analysis and data collection of AKR1C3 in 
combination with PQ and/or inhibitors must 
occur before serious conclusions can be 
Figure 7.  Activity (IU/mg) of AKR1C3.  (a) AKR1C3 
activity in the presences of PQ up to 25 µM. Vmax = 
0.47 IU/mg, Km = .435 µM, and KI = 6.29 µM ( 2 = 0.946) 
(b) Activity of AKR1C3 when 1 µM PQ is combined with 
Bisdemethoxycurcumin up to 50 µM.  Vmax = 0.46 
IU/mg, Km = 0.406 µM, and KI = 1.59 µM ( 2 = 0.970) (c) 
Combined graphs of PQ and PQ + 
Bisdemethoxycurcumin (n = 2 – 5).   
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drawn, however.  The crystal structure of 
AKR1C3 with PQ at saturated levels should 
also be studied before this theory can be 
substantiated.   
Regardless of the mechanism of action for 
PQ and AKR1C3, we were able to observe 
the inhibitory effects of curcumin, DMC, 
and BDMC in concentrations ranging from 
10-80 μM.  This indicates these inhibiting 
curcuminoids could be tested on AKR1C3 
tumour cells to determine their efficacy.  
Curcumin has already proven to elevate 
AKR1C2 expression in prostate cancer cells, 
leading to a decrease in tumour size [18].  
This suggests curcumin and its analogues 
would be effective in binding to and 
inhibiting AKR1C3 activity in tumorous cells, 
as AKR1C2 and AKR1C3 share 84 percent 
similarity [1].  Curcumin and its analogues 
could theoretically bind to the active site of 
AKR1C3, as the carbonyl group in 
curcuminoids should form strong hydrogen 
bonds with the Tyr55 and His117 residues of 
AKR1C3.  Tyr55 and His117 can act as an 
anchor in the active site for ligands that 
contain a carbonyl or carboxylate group, 
allowing for the reduction action to 
proceed [19, 23].  BDMC may also have 
increased stability due to the lack of 
methoxy groups on the aryl ring, as 
mentioned previously.   
Inhibition of AKR1C3 by curcuminoids could 
potentially prevent excess cell proliferation 
by decreasing the amount of PGF2α and 
9α,11β-PGF2α activating the prostaglandin F 
(FP) receptor via ligand binding to the 
receptor itself or binding to the Gq coupled 
FP receptor [24, 25].  This in turn would inhibit 
FP from activating, via downstream, cross-
signalling events, receptor tyrosine kinases 
(RTKs), which lead to the activation of the 
mitogen-activated protein kinase (MAPK) 
and phosphatidylinositol 3-kinase (PI3K) 
pathways that target gene transcription 
[26].  Over-activation of the AR or ER by 
AKR1C3 can additionally cause gene 
overexpression due to its role as a DNA-
binding transcription factor [27], suggesting 
inhibition would decrease the proliferation 
of androgen- and oestrogen-related 
diseases and cancers.  Furthermore, 
inhibition of AKR1C3 has shown to increase 
PPARγ activity in cancerous cells, leading 
to increased cell differentiation and 
apoptosis [28-30].  This would imply that 
inhibition of AKR1C3 by curcuminoids 
would also increase PPARγ activity in 
tumour cells, leading to a reduction in 
tumour size.      
Despite these encouraging results on the 
inhibitory activity of curcumin, DMC, and 
BDMC on AKR1C3, more data needs to be 
collected in a stable environment.  As an 
enzyme, AKR1C3 is sensitive to temperature 
and pH.  This was extremely evident in our 
experiments due to the inability to control 
the room temperature.  Temperatures 
could range anywhere from 18°C to 26°C in 
our laboratory, which would affect the 
activity of AKR1C3.  On warmer days the 
activity was typically higher than cooler 
days.  However, we tried to mitigate this 
obstacle by measuring a daily standard of 
1 μM PQ with no inhibitor and comparing 
the daily results to this standard.  We would 
then calculate the daily activity compared 
Figure 8.  AKR1C3 structure.  The catalytic tetrad within 
the active site is emphasized by Asp50, Tyr55, Lys84, and 
His117 residues.  The loops around the active site and 




to our PQ standard curve (Fig. 4a), which 
was measured and calculated in one day.   
Temperature, along with pH, has also 
shown to affect the whether the keto-enol 
tautomers of curcuminoids exist in their 
trans or cis form, thereby affecting their 
activity [31-33].  This again was observed in 
our results, as there was a change in 
inhibitor activity based upon the room 
temperature.  We also noticed a difference 
in activity when a new potassium 
phosphate buffer was used, as the buffer 
was originally slightly more acidic (pH = 6.4) 
then the required pH for the buffer (pH = 
6.5).  This emphasised curcumin’s sensitivity 
to pH, as it has shown to be more stable in 
acidic environments compared to neutral 
and basic [34], and less soluble in acidic 
and neutral environments compared to 
basic environments [35].  Such 
considerations must be contemplated 
when using curcumin or its derivatives as a 
therapeutic tool in humans, as there is a 
neutral-to-slightly basic physiological pH in 
blood and plasma.      
Future experiments, in addition to being 
conducted in a stable environment, should 
collect more data points at different 
concentrations of PQ when applied in 
conjunction with a constant concentration 
of BDMC.    As the more potent inhibitor in 
our experiment, BDMC can be used to 
establish if it is truly mixed inhibition 
occurring when applied to AKR1C3.  
Unfortunately, due to time and materials 
constraints, we were only able to collect 
five data points in duplicate for 1 μM PQ 
and varying BDMC concentrations.  This 
was also true for 10 μM BDMC and varying 
PQ concentrations.  It would also be 
beneficial to analyse the molecular 
components of the several-month old 
bottle of BDMC to see if any molecular 
degradation has occurred that could alter 
its activity.  If so, this could be used as a 
model for a future curcumin analogue in 
cancer treatment. 
Conclusions 
AKR1C3 has a regulating role in several 
cellular proliferation and differentiation 
pathways.  Overexpressed AKR1C3 can 
result in prolific PGs and 
androgens/oestrogens that influence gene 
transcription in several different cancers 
and diseases.  The ability to inhibit 
overactive AKR1C3 could decrease cell 
proliferation while increasing differentiation 
and apoptosis.   
Widely studied as a potential treatment 
option for cancer, curcumin has shown 
inhibitory activities on tumorous cell lines.  
However, due to its poor bioavailability and 
stability, it has not been terribly successful in 
vivo.  This has led to the development and 
use of curcumin analogues with greater 
bioavailability and stability.  Previous 
research has shown naturally occuring 
DMC and BDMC to be more potent than 
curcumin, suggesting they could be more 
effective in inhibiting AKR1C3.   In an 
attempt to inhibit AKR1C3 activity in 
transformed E. coli cells, we used the 
polyphenol curcumin and its analogues 
DMC and BDMC.   
Enzyme assays measuring the oxidation 
rate of the AKR1C3 co-activator NADPH 
found the inhibitor potency to be BDMC > 
DMC > curcumin, as seen in previous 
research.  Further analysis of BDMC 
indicated a type of mixed inhibition.  
AKR1C3 activity was found to have a 
constant Vmax in the presence and 
absence of BDMC, but a lower Km in the 
presence of BDMC compared to the 
absence of BDMC.  Additional experiments 
must be conducted to confirm this type of 
inhibition.  
Interestingly, we observed AKR1C3 did not 
follow Michaelis-Menten kinetics at higher 
concentrations of substrate with or without 
an inhibitor.  This indicates there may be a 
second binding site within the AKR1C3 
enzyme that allows for self-inhibition, which 
has not yet been reported to our 
knowledge.  This possibility could have 
great implications in drug development 
and targeting of AKR1C3 for cancer 
treatment.  The crystal structure of AKR1C3 
with PQ as its substrate should be explored 
above substrate saturation to determine if 
a hidden binding site is exposed.  If so, this 
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potential binding site could be utilised in 
addition to AKR1C3 inhibitors, as the 
inhibitory effectiveness increased as the PQ 
substrate concentration increased. 
In support of previous research, we found 
that BDMC is a more potent inhibitor of 
AKR1C3 activity in transformed E. coli cells.  
More data must be collected to confirm 
mixed inhibition, as curcumin and AKR1C3 
has shown different inhibition activities 
depending on the molecule they are 
binding to.  Further analysis of the structure 
of AKR1C3 must also be explored to 
determine if an additional binding site does 
not appear upon substrate saturation and 
lead to self-inhibition of the enzyme. 
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